Lv75
4994 积分 2022-11-08 加入
Spontaneous Fluctuations of Tumor-Informed Circulating Tumor DNA at Low Levels
9天前
已关闭
EMPIRE (NSABP FC-13): a biomarker-driven phase II platform trial evaluating cemiplimab-based immunotherapy in microsatellite-stable colorectal cancer with ctDNA-defined minimal residual disease
10天前
已完结
Circulating tumor DNA-guided adjuvant therapy in locally advanced colon cancer: the randomized phase 2/3 DYNAMIC-III trial
18天前
已完结
ctDNA-Guided Adjuvant Atezolizumab in Muscle-Invasive Bladder Cancer
21天前
已完结
Nonoperative Management of Mismatch Repair–Deficient Tumors
1个月前
已完结
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study
1个月前
已完结
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
2个月前
已完结
LEAP-008: Lenvatinib Plus Pembrolizumab for Metastatic NSCLC That Has Progressed After an Anti–Programmed Cell Death Protein 1 or Anti–Programmed Cell Death Ligand 1 Plus Platinum Chemotherapy
2个月前
已完结
Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial
2个月前
已完结
First-line penpulimab combined with paclitaxel and carboplatin for metastatic squamous non-small-cell lung cancer in China (AK105-302): a multicentre, randomised, double-blind, placebo-controlled phase 3 clinical trial
2个月前
已完结
皖公网安备34019202002308
